fig2

Figure 2. Comparison of DFS between different groups and diagnostic ability for recurrence of various clinical indices. (A) Median DFS between preoperative ctDNA positive and negative patients was 15 months vs. 77 months, P: 0.003, HR: 2.88 (95%CI: 1.23-6.71); (B) Preoperative ctDNA status ranked first place in predicting postoperative recurrence among other parameters assessed with an AUC of 0.75. DFS: Disease-free survival; ctDNA: circulating tumor DNA; HR: hazard ratio; AUC: area under the curve; ROC: receiver operating characteristic; DCP: des-γ-carboxy prothrombin.